|
SI1478394T1
(sl)
|
2002-02-27 |
2008-12-31 |
Immunex Corp |
STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
|
|
MXPA05010555A
(es)
|
2003-04-04 |
2006-03-09 |
Genentech Inc |
Formulaciones de proteina y anticuerpo de alta concentracion.
|
|
US7303748B2
(en)
|
2005-02-02 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a VEGF inhibitor
|
|
ES2633574T3
(es)
|
2005-03-25 |
2017-09-22 |
Regeneron Pharmaceuticals, Inc. |
Formulaciones de antagonistas de VEGF
|
|
BRPI0611901A2
(pt)
|
2005-06-14 |
2012-08-28 |
Amgen, Inc |
composição, liofilizado, kit, e, processo para preparar uma composição
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
CA2654510C
(en)
|
2006-06-16 |
2015-03-17 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
CN103816115B
(zh)
|
2010-08-31 |
2017-06-27 |
成都康弘生物科技有限公司 |
一种含有抑制血管增生的融合蛋白的药物组合物及用途
|
|
ES2985784T3
(es)
|
2011-11-18 |
2024-11-07 |
Regeneron Pharma |
Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares
|
|
JP6313712B2
(ja)
|
2011-12-21 |
2018-04-18 |
アムジエン・インコーポレーテツド |
新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド
|
|
CN103212075B
(zh)
|
2012-01-19 |
2017-06-27 |
成都康弘生物科技有限公司 |
一种含有vegf拮抗剂的滴眼液
|
|
US20130323242A1
(en)
*
|
2012-06-01 |
2013-12-05 |
Ophthotech Corp. |
Compositions comprising an anti-pdgf aptamer and a vegf antagonist
|
|
AU2013267310A1
(en)
|
2012-06-01 |
2014-12-11 |
Ophthotech Corporation |
Compositions comprising an anti-PDGF aptamer and a VEGF antagonist
|
|
UA115789C2
(uk)
*
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
WO2014078627A1
(en)
|
2012-11-19 |
2014-05-22 |
Merck Sharp & Dohme Corp. |
Liquid formulations for tnfr:fc fusion proteins
|
|
CA2926853C
(en)
|
2013-10-18 |
2022-04-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
|
|
CN105435222B
(zh)
|
2014-09-25 |
2018-05-29 |
信达生物制药(苏州)有限公司 |
重组融合蛋白制剂
|
|
KR101808234B1
(ko)
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
|
|
EP3362041B1
(en)
|
2015-10-16 |
2026-04-08 |
Regeneron Pharmaceuticals, Inc. |
Stable protein compositions
|
|
ES2981791T3
(es)
|
2015-12-16 |
2024-10-10 |
Regeneron Pharma |
Composiciones y métodos para fabricar micropartículas de proteína
|
|
US10576128B2
(en)
|
2016-01-26 |
2020-03-03 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
EP3436473A4
(en)
|
2016-03-29 |
2019-10-23 |
Navya Biologicals Pvt. Ltd. |
METHOD FOR PURIFYING FC FUSION PROTEINS
|
|
KR101685532B1
(ko)
|
2016-04-26 |
2016-12-13 |
한국프라임제약주식회사 |
혈관내피성장인자 수용체 융합단백질
|
|
EP3518971A4
(en)
|
2016-09-28 |
2020-05-13 |
Board Of Regents, The University Of Texas System |
ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
|
|
PT3528787T
(pt)
|
2016-10-21 |
2026-03-11 |
Amgen Inc |
Formulações farmacêuticas e métodos para produzir as mesmas
|
|
JP7116059B2
(ja)
|
2016-11-21 |
2022-08-09 |
ジャスト－エヴォテック バイオロジックス、インコーポレイテッド |
アフリベルセプト製剤及びその使用
|
|
CR20190291A
(es)
|
2016-12-23 |
2019-11-05 |
Serum Institute Of India Pvt Ltd |
Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
|
|
KR101861163B1
(ko)
*
|
2017-04-26 |
2018-05-25 |
삼천당제약주식회사 |
안과용 약학 조성물
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
US20200255496A1
(en)
|
2017-09-18 |
2020-08-13 |
Amgen Inc. |
Vegfr-fc fusion protein formulations
|
|
CN107595765A
(zh)
|
2017-09-22 |
2018-01-19 |
沈阳兴齐眼药股份有限公司 |
一种眼用缓释药物递送系统及其制备方法
|
|
MX2020005170A
(es)
|
2017-11-17 |
2020-10-16 |
Amgen Inc |
Formulaciones de proteinas de fusion vegfr-fc.
|
|
MY202872A
(en)
|
2017-11-20 |
2024-05-28 |
Just Evotec Biologics Inc |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
WO2019124946A1
(ko)
|
2017-12-22 |
2019-06-27 |
삼성바이오에피스 주식회사 |
Vegf 길항제를 포함하는 액상 조성물
|
|
EP3761953A1
(en)
*
|
2018-03-08 |
2021-01-13 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
DK4364724T3
(da)
|
2018-05-10 |
2025-12-22 |
Regeneron Pharma |
Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
|
|
WO2020055123A1
(ko)
|
2018-09-10 |
2020-03-19 |
삼성바이오에피스 주식회사 |
단백질을 포함하는 액상 조성물
|
|
US20210353713A1
(en)
|
2018-10-26 |
2021-11-18 |
Amgen Inc. |
Formulations comprising a tris buffer and a protein
|
|
EP3923907B1
(en)
|
2019-02-13 |
2024-09-25 |
Novaliq GmbH |
Compositions and methods for the treatment of ocular neovascularization
|
|
GB201911461D0
(en)
|
2019-08-09 |
2019-09-25 |
Arecor Ltd |
Novel composition
|
|
WO2021050687A1
(en)
|
2019-09-10 |
2021-03-18 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|